Complete Guide to Tacrolimus (Advagraf) Pharmacokinetics
Overview
Tacrolimus (Advagraf) is a Calcineurin Inhibitor used in the Transplant Immunosuppression therapeutic area. It is indicated for Maintenance immunosuppression after kidney transplantation. Population PK simulator for once-daily tacrolimus extended-release (Advagraf), a calcineurin inhibitor used after kidney transplantation. Includes CYP3A5 genotype effects on oral exposure and clearance.
Mechanism of Action
Tacrolimus (Advagraf) exerts its pharmacological effect by targeting Calcineurin via FKBP12 complex. As a Calcineurin Inhibitor, it modulates this target to achieve therapeutic efficacy in Maintenance immunosuppression after kidney transplantation. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This Population PK model for Tacrolimus (Advagraf) characterizes the time-course of drug concentrations following Oral extended-release administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
Tacrolimus (Advagraf) is administered via the Oral extended-release route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Transplant Immunosuppression therapeutic area, for the treatment of Maintenance immunosuppression after kidney transplantation, understanding the pharmacokinetics of Tacrolimus (Advagraf) is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Tacrolimus (Advagraf) pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Tacrolimus (Advagraf) PK Simulator
Explore Tacrolimus (Advagraf) pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Tacrolimus (Advagraf)?
The elimination half-life of Tacrolimus (Advagraf) depends on patient-specific factors. Use our interactive Tacrolimus (Advagraf) PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Tacrolimus (Advagraf) administered?
Tacrolimus (Advagraf) is administered via the Oral extended-release route. It is indicated for Maintenance immunosuppression after kidney transplantation. As a Calcineurin Inhibitor, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Tacrolimus (Advagraf)?
Key pharmacokinetic parameters for Tacrolimus (Advagraf) include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a Population PK model to characterize the pharmacokinetics of Tacrolimus (Advagraf).
Can I simulate Tacrolimus (Advagraf) dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Tacrolimus (Advagraf) PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.